What is the clinical significance of the findings from the delayed-start trial of rasagiline in Parkinson's disease?
Vanacore
Nicola
N
D004334:Drug Administration Schedule; D006801:Humans; D007189:Indans / Q000008:administration & dosage*; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D010300:Parkinson Disease / Q000145:classification* / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design
D007189:Indans; D018696:Neuroprotective Agents; C031967:rasagiline